Bipolar Depression Market is set for steady growth, with a robust CAGR anticipated by 2034, estimates DelveInsight | Allergan (AbbVie)/Gedeon Richter, Alkermes, Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc.,

DelveInsight's "Bipolar Depression Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Bipolar Depression market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Bipolar Depression Market with DelveInsight's In-Depth Report @ Bipolar Depression Market Size- https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Bipolar Depression Market Report
• As per DelveInsight's estimates, diagnosed prevalent cases of bipolar depression in the United States was around 70% of the total cases in the 7MM in 2023.
• In the United States, severe cases constituted the maximum number of cases based on severity with approximately 75% cases in 2023.
• Among the 7MM, the highest number of treated cases of bipolar depression was observed in the United States, which accounted for more than 60% of the total treated cases in 2023.
• Germany accounted for the highest diagnosed prevalent cases of bipolar depression in 2023 among the EU4 and the UK.
• The leading Bipolar Depression Companies such as Allergan (AbbVie)/Gedeon Richter, Alkermes, Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
• Promising Bipolar Depression Therapies such as VRAYLAR (Cariprazine), LYBALVI (olanzapine, samidorphan L-malate), NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others

Stay ahead in the Bipolar Depression Therapeutics Market with DelveInsight's Strategic Report @ Bipolar Depression Market Outlook- https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bipolar Depression Epidemiology Segmentation in the 7MM
• Total Bipolar Depression Prevalence
• Prevalent Cases of Bipolar Depression by severity
• Bipolar Depression Gender-specific Prevalence
• Diagnosed Cases of Episodic and Chronic Bipolar Depression

Download the report to understand which factors are driving Bipolar Depression epidemiology trends @ Bipolar Depression Prevalence- https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bipolar Depression Marketed Drugs
• VRAYLAR (Cariprazine): Allergan (AbbVie)/Gedeon Richter
VRAYLAR is an oral capsule containing cariprazine as an active ingredient. It is approved in the US for schizophrenia, bipolar disorder, and bipolar depression. VRAYLAR was discovered and co-developed by Gedeon Richter Plc and is licensed by Allergan in the US. In May 2019, the US FDA approved a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for expanded use to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults. The FDA approval for the expanded indication of VRAYLAR was based on three pivotal trials, including RGH-MD-53, RGH-MD-54, and RGH-MD-56, in which cariprazine demonstrated greater improvement than placebo for the change from baseline to weeks on the Montgomery - Asberg Depression Rating Scale (MADRS) total score.

• LYBALVI (olanzapine, samidorphan L-malate): Alkermes
LYBALVI is composed of olanzapine, an established antipsychotic agent, co-formulated with samidorphan, a new chemical entity, in a single bilayer tablet. In Jun 2021, the US. FDA approved Lybalvi (olanzapine and samidorphan) for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. The FDA approval of Lybalvi was supported by the results of the ENLIGHTEN program's pivotal ENLIGHTEN-1 efficacy study and ENLIGHTEN-2 weight study.

Bipolar Depression Emerging Drugs
• NRX-100 and NRX-101: NeuroRx
NeuroRx has developed a sequential therapy consisting of intravenous NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation followed by oral NRX-101 (fixed-dose combination of D-cycloserine and lurasidone) for maintenance of stabilization of symptoms of depression and suicidal ideation. In September 2017, the US FDA granted fast track designation to NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone) for bipolar depression with suicidal ideation.

• COMP 360 (Psilocybin): COMPASS Pathways
Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as 'magic mushrooms.' COMPASS Pathways have developed a synthesized formulation of psilocybin, COMP360, and is investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression/bipolar depression

Get In-Depth Knowledge on Bipolar Depression Market Trends and Forecasts with DelveInsight @ Bipolar Depression Treatment Market- https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Bipolar Depression Market Report
• Coverage- 7MM
• Bipolar Depression Companies- Allergan (AbbVie)/Gedeon Richter, Alkermes, Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
• Bipolar Depression Therapies- VRAYLAR (Cariprazine), LYBALVI (olanzapine, samidorphan L-malate), NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
• Bipolar Depression Market Dynamics: Bipolar Depression Market Drivers and Barriers
• Bipolar Depression Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight's Comprehensive Bipolar Depression Market Report @ Bipolar Depression Market Drivers and Barriers- https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Bipolar Depression Market Overview at a Glance
4. Executive Summary of Bipolar Depression
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Bipolar Depression: 7 Major Market Analysis
13. Market Access and Reimbursement
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Surgical Lasers Market - https://www.delveinsight.com/report-store/surgical-lasers-market
Intraocular Lens Market - https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Myeloproliferative Neoplasms Market - https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
Skin Neoplasm Market - https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
Healthcare Competitive Benchmarking - https://www.delveinsight.com/consulting/competitive-benchmarking-services
Microscopy Device Market - https://www.delveinsight.com/report-store/microscopy-device-market
Pacemakers Market - https://www.delveinsight.com/report-store/pacemakers-market
Urea Cycle Disorders Market - https://www.delveinsight.com/blog/urea-cycle-disorder-market
Novel Drug Delivery Devices Market - https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Nk Cell Therapy Market - https://www.delveinsight.com/infographics/nk-cell-therapy-market
Surgical Mask & Respirator Market - https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Lymphoedema Market - https://www.delveinsight.com/report-store/lymphoedema-market
Phototherapies For Psoriasis Market - https://www.delveinsight.com/report-store/phototherapy-devices-market
Sepsis Market - https://www.delveinsight.com/report-store/sepsis-market
Bone Growth Stimulator Market - https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody Drug Conjugate Market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
Overactive Bladder Syndrome Market - https://www.delveinsight.com/report-store/underactive-bladder-market
Medical Marijuana Market - https://www.delveinsight.com/report-store/medical-marijuana-market
Lactose Intolerance Market - https://www.delveinsight.com/report-store/lactose-intolerance-market
Catheter Stabilization Devices Market - https://www.delveinsight.com/sample-request/catheter-stabilization-securement-device-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/knee-reconstruction-devices-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.